Cynata Therapeutics Ltd
CYP
Company Profile
Business description
Cynata Therapeutics Ltd is engaged in the development and commercialization of a proprietary mesenchymal stem cell (MSC) technology for potential human therapeutic use, which is branded as Cymerus manufacturing platform. There are currently three active clinical trials taking place using Cymerus technology, which are attempting to treat osteoarthritis and others.
Contact
100 Cubitt Street
Level 3
CremorneVIC3121
AUST: +61 370676940
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
Employees
2
Stocks News & Analysis
stocks
A better way to predict long-term stock returns
A value-weighted version of the CAPE ratio corrects a structural flaw and delivers stronger forecasts of long-term stock returns.
stocks
Five star stock added to August best ideas list
Morningstar analysts hand pick this undervalued opportunity for their August global best ideas.
stocks
Undervalued supermarket share sees sales improvement
Improving sales trends but recovery remains gradual.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,919.90 | 0.30 | -0.00% |
| CAC 40 | 8,179.77 | 63.01 | 0.78% |
| DAX 40 | 25,568.56 | 207.41 | 0.82% |
| Dow JONES (US) | 52,573.29 | 509.19 | 0.98% |
| FTSE 100 | 10,650.44 | 41.52 | 0.39% |
| HKSE | 24,862.09 | 56.46 | 0.23% |
| NASDAQ | 26,333.04 | 251.31 | 0.96% |
| Nikkei 225 | 63,401.37 | 609.97 | -0.95% |
| NZX 50 Index | 13,560.69 | 19.64 | -0.14% |
| S&P 500 | 7,656.98 | 65.28 | 0.86% |
| S&P/ASX 200 | 8,743.80 | 2.60 | 0.03% |
| SSE Composite Index | 3,885.93 | 2.18 | -0.06% |